MARC record from Internet Archive

LEADER: 05668cam 22006254a 4500
001 ocn192079717
003 OCoLC
005 20180506061606.0
008 080306s2008 miu b 001 0 eng
010 $a 2008010058
040 $aDLC$beng$cDLC$dYDX$dBTCTA$dYDXCP$dBAKER$dSVW$dJED$dQBX$dOCLCQ$dBDX$dOCLCF$dOCLCO$dCOVAL$dOCLCQ$dMYUKM$dOCLCO$dUX0$dOCLCA
019 $a192079718
020 $a9780737739626$q(hardcover)
020 $a0737739622$q(hardcover)
020 $a9780737739633$q(pbk.)
020 $a0737739630$q(pbk.)
035 $a(OCoLC)192079717$z(OCoLC)192079718
050 00 $aRM301.15$b.P735 2008
060 $aQV736$b.P928 2008 9HUKMTL
082 00 $a338.4/76151$222
082 14 $a615$214
245 00 $aPrescription drugs /$cSylvia Engdahl, book editor.
260 $aDetroit :$bGreenhaven Press/Gale Cengage Learning,$c℗♭2008.
300 $a246 pages ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aCurrent controversies
504 $aIncludes bibliographical references (pages 227-235) and index.
505 00 $tIs too little attention given to the safety of prescription drugs? Yes : Problems often show up after a prescription drug is on the market. Off-label prescription of drugs can lead to adverse effects /$rHazel Muir --$tSome prescription drugs on the market are unsafe /$rConsumer reports --$tPrescription drugs can cause serious harm when risks are ignored /$rSusan Kelleher --$tPost-marketing study of prescription drugs is not adequate /$rDavid J. Graham --$tNo : Too much caution deprives patients of prescription drugs they need. Excessive caution in drug approval causes more harm than it prevents /$rScott Gottlieb --$tPanic over prescription-drug risks leads people to stop taking needed medication /$rIrene S. Levine --$tSafety concerns about prescription drugs are exaggerated and will result in higher prices /$rHenry I. Miller --$tLengthy approval process for prescription drugs costs lives /$rGilbert L. Ross --$tTerminally ill patients should be allowed to use experimental drugs /$rSigrid Fry-Revere --$tDo pharmaceutical companies promote unnecessary drugs? Direct-to-consumer prescription drug advertising : an overview /$rCarol Rados --$tYes : Many new drugs are developed merely for commercial reasons. Pharmaceutical companies define normal conditions as diseases /$rRay Moynihan, Alan Cassels --$tDrug promotion plays on people's fears of future illness /$rBarbara Mintzes --$tDrug promotion has led to the overmedication of children /$rAnne Taylor Fleming --$tNo : New drugs help people who would otherwise lack effective treatment. Drugs for minor conditions are important to many people /$rGlenn Harlan Reynolds --$tImproved prescription drugs mean better medical treatment and less illness /$rAlan F. Holmer --$tDirect-to-consumer prescription drug advertising helps people get treatment for undiagnosed diseases /$rPaul Antony.
505 00 $tDo prescription drugs in America cost too much? Rising cost of prescription drugs : an overview --$tYes : American pharmaceutical companies charge too much. Many people cannot afford the prices set by the profit-driven drug industry /$rKatharine Greider --$tImporting less-costly prescription drugs from abroad should be allowed /$rNelda Barnett --$tNew cancer drugs cost more than their brief extending of life may be worth /$rDaniel Costello --$tNo : pharmaceutical companies need profits to do research. High prices of drugs for minor problems pay for drugs that cure more serious ones /$rPeter W. Huber --$tMedical innovation would stop if the government controlled drug prices /$rSidney Taurel --$tControlling drug prices would reduce access to medicine /$rDoug Bandow --$tAre dishonest or illegal prescription drug practices common? Gifts from pharmaceutical companies influence doctors /$rAdriane Fugh-Berman, Shahram Ahari --$tMedia reporting about prescription drugs is often inaccurate /$rRichard A. Deyo, Donald L. Patrick --$tPrescription drugs are often abused /$rNichole Aksamit --$tYoung people often trade prescription drugs with friends /$rAmy Harmon --$tTeens use prescription drugs to get high /$rDonna Leinwand.
520 $aAuthors debate issues on prescription drugs from the safety and effectiveness of prescription drugs to the promotion and marketing of new products to the cost of prescription medications.
650 0 $aDrugs$xPublic opinion.
650 0 $aPharmaceutical industry.
650 0 $aPharmaceutical policy.
650 7 $aDrugs$xPublic opinion.$2fast$0(OCoLC)fst00898888
650 7 $aPharmaceutical industry.$2fast$0(OCoLC)fst01060129
650 7 $aPharmaceutical policy.$2fast$0(OCoLC)fst01060194
650 2 $aDrug Industry.
650 2 $aDrug and Narcotic Control.
700 1 $aEngdahl, Sylvia.
776 08 $iOnline version:$tPrescription drugs.$dDetroit : Greenhaven Press/Gale Cengage Learning, ℗♭2008$w(OCoLC)768252756
830 0 $aCurrent controversies.
856 41 $3Table of contents$uhttp://catdir.loc.gov/catdir/toc/ecip0812/2008010058.html
938 $aBaker & Taylor$bBKTY$c37.40$d37.40$i0737739622$n0007626675$sactive
938 $aBaker & Taylor$bBKTY$c25.95$d25.95$i0737739630$n0007626676$sactive
938 $aBrodart$bBROD$n07459343$c$28.35
938 $aBaker and Taylor$bBTCP$n2008010058
938 $aQuality Books, Inc.$bQUAL$na 08010058
938 $aYBP Library Services$bYANK$n2776600
938 $aYBP Library Services$bYANK$n2776598
029 1 $aNZ1$b12526644
029 1 $aQBX$ba 08010058
994 $aZ0$bPMR
948 $hNO HOLDINGS IN PMR - 372 OTHER HOLDINGS